title: Radiotherapy for head and neck cancer in nonagenarian patients: a possible cornerstone?
abstract: In the field of radiotherapy, there is very little scientific data on the management of nonagenarians, especially in patients aged 90 years or more and with head and neck cancer (HNC). We made one of the first retrospective study of the feasibility and safety of radiotherapy in this population with HNC. Records of radiotherapy coming from four health facilities were studied to include all nonagenarian patients with HNC in the last 10 years and who received radiation therapy. We analyzed patient characteristics and primary cancers, as well as objective of the treatment (curative or palliative), efficacy and toxicity. Twenty patients receiving radiotherapy were identified; mean age was 93.2 years (standard deviation 2.8). Treatment was given with curative and palliative intent in 40 and 60 % of cases, respectively. The most common primary tumors were tumors of the salivary glands (30 % of cases), oral cavity tumors (25 % of cases) and thyroid tumors (15 % of cases). Median total prescribed dose was 47.5 Gy (12-70 Gy). Median number of delivered fractions was 18.5 (2-35 fractions). All patients received intensive supportive care during radiotherapy. Toxicities were mild to moderate. Radiotherapy could not be completed for four patients (20 % of cases). One patient developed grade 1-2 delayed toxicities. At the last follow-up, only four patients (20 % of cases) were alive. Cancer was cause of death in most cases. Radiotherapy may be performed for the nonagenarians with HNC. The total dose and fractionation must be adjusted to optimize the tolerance. However, the prognosis remains very poor, cancer being the main cause of death. Research of geriatric vulnerabilities prior to any treatment, in the context of a comprehensive geriatric assessment, is still recommended to select patients for radiotherapy.
authors.affiliation: Department of Medical Oncology, Institut Lucien Neuwirth, St Priest en Jarez Cedex, France.
authors.forename: Romain
authors.initials: R
authors.lastname: Rivoirard
authors.forename: Coralie
authors.initials: C
authors.lastname: Moncharmont
authors.forename: Avi
authors.initials: A
authors.lastname: Assouline
authors.forename: Pierre
authors.initials: P
authors.lastname: Auberdiac
authors.forename: Benoite
authors.initials: B
authors.lastname: Mery
authors.forename: Alexander Tuan
authors.initials: AT
authors.lastname: Falk
authors.forename: Pierre
authors.initials: P
authors.lastname: Annède
authors.forename: Jane-Chloé
authors.initials: JC
authors.lastname: Trone
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Guy
authors.forename: Nicolas
authors.initials: N
authors.lastname: Vial
authors.forename: Pierre
authors.initials: P
authors.lastname: Fournel
authors.forename: Yacine
authors.initials: Y
authors.lastname: Merrouche
authors.forename: Cyrus
authors.initials: C
authors.lastname: Chargari
authors.forename: Nicolas
authors.initials: N
authors.lastname: Magné
mesh_terms: D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy; D005240:Feasibility Studies; D005260:Female; D005602:France / Q000453:epidemiology; D006258:Head and Neck Neoplasms / Q000401:mortality* / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D010166:Palliative Care; D018579:Patient Selection; D011379:Prognosis; D011879:Radiotherapy Dosage; D012189:Retrospective Studies